{"id":4204,"date":"2025-03-31T18:12:01","date_gmt":"2025-03-31T18:12:01","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/mitoxantrone-txt\/"},"modified":"2025-03-31T18:12:01","modified_gmt":"2025-03-31T18:12:01","slug":"mitoxantrone-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/mitoxantrone-txt\/","title":{"rendered":"Mitoxantrone.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nMetastatic breast cancerNon-Hodgkin\u2019s lymphomaAdult acute non-lymphocytic leukaemia

DOSE IN NORMAL RENAL FUNCTION <\/H3>Metastatic breast cancer, non-Hodgkin\u2019s lymphoma and hepatoma: 14 mg\/m2 every 21 days (12 mg\/m2 or less if inadequate bone marrow reserves)Adult acute non-lymphocytic leukaemia: 12 mg\/m2 for 5 consecutive daysOr according to local protocol

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :517.4 (as hydrochloride)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :78<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 7<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1000 L\/m2<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :5\u201318 days

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsOther antineoplastic agents: enhanced myelosuppression \u2013 when used in combination reduce mitoxantrone dose by 2\u20134 mg\/m2Cardiotoxic drugs: increased risk of cardiac toxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>

    IV infusion <\/H4>

    Rate of Administration <\/H4>At least 3 minutes

    Comments<\/H4>Dilute to at least 50 mL in sodium chloride 0.9%, glucose 5% or sodium chloride 0.18% and glucose 4%

    OTHER INFORMATION <\/H4>Has been administered intraperitoneally at a dose of 28\u201338 mg\/m2 every 3\u20134 weeks although some people advise a maximum dose of only 30 mg\/m2 per month with a dwell time of 1\u20134 hours. (Alberts DS, Surwit EA, Peng YM, et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res. 1988, Oct 15; 48(20): 5874\u20137)Extensive metabolism in the liver. Excretion is predominantly via the bile and faeces. 5\u201310% of dose is excreted in the urine within 5 days.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Metastatic breast cancerNon-Hodgkin\u2019s lymphomaAdult acute non-lymphocytic leukaemia DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4204","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4204"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4204\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}